BiVacor announced today that the FDA granted investigational device exemption (IDE) for its total artificial heart (BTAH). IDE approval allows BiVacor to begin its first-in-human early feasibility study (EFS) for the BTAH system. The Houston-based company aims to evaluate BTAH’s safety and feasibility as a bridge to a heart transplant for patients with biventricular heart […]
artificial hearts
BiVacor looks to implant its artificial heart in a person next year
BiVacor has raised $18 million to support the continued development of its preclinical artificial heart device. Cormorant Asset Management and OneVentures, through the OneVentures Healthcare Fund III, led the funding round, according to a March 29 news release from Houston-based BiVacor. The investments will fund the company’s continued research and development and early feasibility first […]
Artificial heart developer Carmat could receive up to €17.5M in funding
Carmat announced today that the European Council selected it to join its EIC Accelerator program for innovative companies in Europe. The total funding could reach €17.5 million ($18.6 million). Paris-based Carmat develops a total artificial heart. It designed the platform to provide a therapeutic alternative for those suffering from end-stage biventricular heart failure. EIC Accelerator […]